Compounds > 3,4-methylenedioxyamphetamine

3,4-methylenedioxyamphetamine and levodopa

3,4-methylenedioxyamphetamine has been researched along with levodopa in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Black, CK; Fadayel, GM; Humphreys, TM; Nieduzak, TR; Schmidt, CJ; Sorensen, SM; Taylor, VL1
Pan, HS; Wang, RY1
Black, CK; Schmidt, CJ; Taylor, VL1
Abbate, GM; Nieduzak, TR; Schmidt, CJ; Taylor, VL1
Barbosa, DJ; Branco, PS; Capela, JP; Carvalho, F; de Lourdes Bastos, M; Duarte, JA; Fernandes, E; Ferreira, LM; Oliveira, JM; Silva, R; Siopa, F1

Other Studies

5 other study(ies) available for 3,4-methylenedioxyamphetamine and levodopa

ArticleYear
The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine.
    European journal of pharmacology, 1992, Sep-22, Volume: 220, Issue:2-3

    Topics: 3,4-Methylenedioxyamphetamine; alpha-Methyltyrosine; Animals; Brain; Corpus Striatum; Dopamine; Electrophysiology; Levodopa; Male; Methyltyrosines; Neurons; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin Antagonists

1992
The action of (+/-)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system.
    Brain research, 1991, Mar-08, Volume: 543, Issue:1

    Topics: 3,4-Methylenedioxyamphetamine; 5-Hydroxytryptophan; alpha-Methyltyrosine; Analysis of Variance; Animals; Cerebral Cortex; Designer Drugs; Dopamine; Electrophysiology; Fenclonine; Levodopa; Male; Methyltyrosines; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Rats; Rats, Inbred Strains; Reference Values; Serotonin

1991
L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.
    European journal of pharmacology, 1991, Oct-02, Volume: 203, Issue:1

    Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Drug Synergism; Fenfluramine; Hippocampus; Levodopa; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Nervous System Diseases; p-Chloroamphetamine; Rats; Rats, Inbred Strains; Serotonin

1991
5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.
    The Journal of pharmacology and experimental therapeutics, 1991, Volume: 256, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Animals; Anti-Arrhythmia Agents; Brain; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Homovanillic Acid; Levodopa; Male; Nomifensine; Piperidines; Rats; Rats, Inbred Strains; Ritanserin; Serotonin Antagonists; Stereoisomerism; Time Factors

1991
Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes.
    British journal of pharmacology, 2012, Volume: 165, Issue:4b

    Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Animals; Antioxidants; Brain; Deoxyepinephrine; Dopamine; Glutathione; Hallucinogens; Hydrogen Peroxide; Levodopa; Male; Membrane Potential, Mitochondrial; Mice; Oxidative Stress; Protein Carbonylation; Serotonin; Synaptosomes

2012